Meet Dr. Mandy Xu
Capabilities
In 2018, Dr. Mandy Xu, Vice President of DMPK, celebrated her tenth anniversary with Pharmaron. It’s a milestone that recognizes one of Pharmaron’s many home-grown leaders and marks ten years since Pharmaron launched its DMPK services platform. These two anniversaries are not coincidental—Mandy was hired to launch in vitro ADMET services at Pharmaron.
Now, Mandy and her team continue to thrive thirteen years later. Since her first day at Pharmaron, Mandy has stayed focused. The tasks have changed over the years, but the end goal has remained the same, which is to provide efficient and high-quality in vitro ADMET services to our partners. She built a state-of-the-art lab in her first year, hired scientists, and validated over 50 assays.
These days, she leads a large research team in in vitro ADMET that provides services for solution properties, drug absorption/transport, drug metabolism, drug-drug interactions, and safety screening. Her scientists deliver high-quality in vitro ADMET data to collaborators in biotech, pharmaceutical companies, and academic institutions worldwide. Projects range from early drug discovery supporting PCC nomination to programs for IND/NDA submission. Mandy also leads a global team responsible for regulated bioanalysis in supporting GLP toxicology and clinical sample analysis studies for small molecules.
Mandy believes her team’s success stems from striving to be chosen as our client’s partner and not solely as a service provider. Accuracy, precision, and reproducibility are key to assessing in vitro ADMET assay quality. This group has built state-of-the-art automation capabilities and high throughput screening platforms to achieve this high quality of assays. In addition, a carefully designed program management system was established to streamline the entire process of assays, from compound reception through assaying and data generation and interpretation to report submission. As a result, Pharmaron can reduce the cycle time and provide more cost-effective solutions and efficient and effective services to clients.
A contributing factor to the excellent services provided is the culture of learning to stay updated on current science and technology. Pharmaron recently held its 2nd DMPK Symposium at its Beijing headquarters, bringing together global leaders from industry and academia. The DMPK scientists gained essential insights from each presentation and had in-depth discussions with speakers on a broad spectrum of DMPK subjects during networking times.
Mandy is proud of her team and their hard work and feels like they are family. As the division grows, Mandy recognizes the importance of strengthening the group bond. To celebrate their success and growth, fun events are planned each year. The fourth singing competition was recently held, called “ADME Voice.” Mandy is eager to plan the next fun event.
About Dr. Mandy Xu
Dr. Mandy Xu is the Vice President of DMPK. She leads an in vitro DMPK research team and a global team for regulated bioanalysis in supporting GLP toxicology and clinical sample analysis studies for small molecules. Dr. Xu obtained her B.Sc. and Ph.D. in Pharmaceutical Sciences from Peking University, where her studies focused on pharmacokinetics, drug distribution, and excretion, in vitro drug metabolism, and metabolite identification by using LC/MSn technology. She has published over 20 research articles in peer-reviewed international journals. She enjoys spending time with her family and playing basketball, badminton, and table tennis in her spare time. She also looks forward to planning her group outings.
Updated July 2021
Learn more about Pharmaron’s DMPK services
